


# Stabilis



## Ganciclovir sodium



Noms commerciaux

Ceptyl	Mexique
Ciganclor	Argentine
Citovirax	Italie
Cymevan	France
Cymeven	Allemagne
Cymevene	Australie, Autriche, Belgique, Brésil, Chili, Colombie, Croatie, Danemark, Egypte, Emirats Arabes Unis, Equateur, Espagne, Finlande, Grande Bretagne, Grèce, Hongrie, Iran, Irlande, Islande, Italie, Luxembourg, Malaisie, Mexique, Norvège, Nouvelle Zélande, Pays bas, Pérou, Pologne, Portugal, Russie, Suède, Suisse, Turquie, Vénézuéla
Cymevir	Brésil
Cytovene	Canada, Etats Unis d'Amérique
Ganciclovir	Allemagne, Argentine, Canada, Chili, Equateur, Etats Unis d'Amérique, France, Mexique
Gavir	Inde
Inglav	Mexique
Natclovir	Inde
Pharcigave	Mexique
Umecortil	Colombie, Mexique
Viraprex	Mexique



### Stabilité des solutions

		20 mg/ml	-8°C		24			3796
		20 mg/ml	25°C		24			3796
		20 mg/ml	5°C		24			3796
		1 & 5 mg/ml	25°C		35			76
		1 & 5 mg/ml	5°C		35			76
		2.5 mg/ml	25°C		5			69

PVC		2.5 mg/ml	4°C		5			69
PVC		0,28 & 1,4 mg/ml	-20°C		365			245
PVC		0,28 & 1,4 mg/ml	25°C		8			245
PVC		0,28 & 1,4 mg/ml	4°C		80			245
PVC		1 >> 2,5 mg/ml	4°C		240			4
PVC		1,5 & 10 mg/ml	4-8°C		35			70
PVC		5 & 10 mg/ml	-20°C		28			88
PVC		5 & 10 mg/ml	4°C		28			88
PP		0,25 mg/ml	2-8°C		185			4021
PP		0,25 mg/ml	23-27°C		185			4021
PP		5 mg/ml	2-8°C		185			4021
PP		5 mg/ml	23-27°C		185			4021
		1,4 & 7 mg/ml	-20°C		365			245
		1,4 & 7 mg/ml	25°C		8			245
		1,4 & 7 mg/ml	4°C		80			245
		5 mg/ml	2-8°C		185			4021
		5 mg/ml	23-27°C		185			4021
		5,8 mg/ml	25°C		12			74
		5,8 mg/ml	4°C		10			74
		1 & 6 mg/ml	25°C		24			604
		1 & 6 mg/ml	4°C		15			604



### Facteur influençant la stabilité

				1415
				67
				301



### Compatibilités

	Ganciclovir sodium : 1 & 5 mg/ml		67
		Ganciclovir sodium : 20 mg/ml	
	Ganciclovir sodium : 0.83 & 1.4 mg/ml		72

		Ganciclovir sodium : 10 mg/ml		67
		Ganciclovir sodium : 20 mg/ml		301
		Ganciclovir sodium : 10 mg/ml Aldesleukin : 0.0338 MUI/ml		36
		Ganciclovir sodium : 20 mg/ml Allopurinol sodium : 3 mg/ml		307
		Ganciclovir sodium : 20 mg/ml Amifostine : 10 mg/ml		3
		Ganciclovir sodium : 20 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Ganciclovir sodium : 20 mg/ml Amsacrine : 1 mg/ml		253
		Ganciclovir sodium : 20 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Ganciclovir sodium : 20 mg/ml Aztreonam : 40 mg/ml		99
		Ganciclovir sodium : 20 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Ganciclovir sodium Ceftazidime		3883
		Ganciclovir sodium : 20 mg/ml Cisatracurium besylate : 0.1 & 2 mg/ml		299
		Ganciclovir sodium : 20 mg/ml Cisatracurium besylate : 5 mg/ml		299
		Ganciclovir sodium : 10 mg/ml Defibrotide : 8 mg/ml		3728
		Ganciclovir sodium : 20 mg/ml Docetaxel : 0.9 mg/ml		1754
		Ganciclovir sodium : 20 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Ganciclovir sodium : 5 mg/ml Enalaprilate : 1.25 mg/ml		201
		Ganciclovir sodium : 20 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Ganciclovir sodium : 20 mg/ml Filgrastim : 30 µg/ml		244
		Ganciclovir sodium : 50 mg/ml Fluconazole : 2 mg/ml		496
		Ganciclovir sodium : 20 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Ganciclovir sodium Foscarnet sodium		3662
		Ganciclovir sodium : 50 mg/ml Foscarnet sodium : 24 mg/ml		73
		Ganciclovir sodium : 20 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Ganciclovir sodium : 20 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Ganciclovir sodium : 20 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Ganciclovir sodium : 20 mg/ml Linezolid : 2 mg/ml		1925

		Ganciclovir sodium : 20 mg/ml Melphalan : 0.1 mg/ml		169
		Ganciclovir sodium : 20 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Ganciclovir sodium : 20 mg/ml Paclitaxel : 1.2 mg/ml		248
		Ganciclovir sodium : 20 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Ganciclovir sodium : 20 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Ganciclovir sodium : 20 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Ganciclovir sodium : 3,5 mg/ml Posaconazole : 1,2 mg/ml		4521
		Ganciclovir sodium : 20 mg/ml Propofol : 10 mg/ml		300
		Ganciclovir sodium : 20 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
		Ganciclovir sodium : 20 mg/ml Sargramostim : 10 µg/ml		335
		Ganciclovir sodium : 50 mg/ml Tacrolimus : 1000 µg/ml		479
		Ganciclovir sodium Tacrolimus		3626
		Ganciclovir sodium : 20 mg/ml Teniposide : 0.1 mg/ml		905
		Ganciclovir sodium : 20 mg/ml Thiotepa : 1 mg/ml		249
		Ganciclovir sodium : 20 mg/ml Vinorelbine tartrate : 1 mg/ml		84



## Voie d'administration



## Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
4	Revue	Zazempa V, Morgenszejn J, Paul M, Astier A. Reconstitution centralisée du ganciclovir : méthode de contrôle et étude de stabilité. Act Pharm Biol Clin 1995 ; 8: 525-528.
36	Revue	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.

59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
67	Revue	Outman WR, Mitrano FP, Baptista RJ. Visual compatibility of ganciclovir sodium and parenteral nutrient solution during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 1538-1539.
69	Revue	Visor GC, Lin LH, Jackson SE, Winterle JS, Lee G, Kenley RA. Stability of ganciclovir sodium (DHPG sodium) in 5% dextrose or 0.9% sodium chloride injections. Am J Hosp Pharm 1986 ; 43: 2810-2812.
70	Revue	Silvestri AP, Mitrano FP, Baptista RJ, Williams DA. Stability and compatibility of ganciclovir sodium in 5% dextrose injection over 35 days. Am J Hosp Pharm 1991 ; 48: 2641-2643.
72	Revue	Johnson CE, Jacobson PA, Chan E. Stability of ganciclovir sodium and amino acids in parenteral nutrient solutions. Am J Hosp Pharm 1994 ; 51: 503-508.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
74	Revue	Mulye NV, Turco SJ, Speaker TJ. Stability of ganciclovir sodium in an infusion-pump syringe. Am J Hosp Pharm 1994 ; 51: 1348-1349.
76	Revue	Parasrampur J, Li LC, Stelmach AH, Sykes TR, Gordon GA. Stability of ganciclovir sodium in 5% dextrose injection and in 0.9% sodium chloride injection over 35 days. Am J Hosp Pharm 1992 ; 49: 116-118.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
88	Revue	Mole L, Oliva C, O'Hanley P. Extended stability of ganciclovir for outpatient parenteral therapy for cytomegalovirus retinitis. J Acquired Immune Defic Syndr 1992 ; 5: 354-358.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
201	Revue	Thompson DF, Allen LV, Stiles ML. Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2530-2531.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
245	Revue	Phaypradith S, Vigneron J, Perrin A, Durney-Archeray MJ, Hoffman MA, Hoffman M. Stability of ganciclovir sodium (Cymevan*) after dilution in PVC infusions and polypropylene syringes. J Pharm Belg 1992 ; 47: 494-498.

248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Revue	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
604	Laboratoire	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.

1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3626	Laboratoire	Tacrolimus (Prograf®) - Résumé des Caractéristiques du Produit Astellas Pharma 2014
3662	Laboratoire	Foscavir (Foscarnet®) - Summary of Product Characteristics Clinigen 2014
3728	Revue	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apiph Congress, Paris November 2014 2014
3796	Revue	Morlet N, Young S, Naidoo D et al. High dose intravitreal ganciclovir for CMV retinitis: a shelf life and cost comparison study. Br Ophthalmol 1995 ; 79: 753-755.
3883	Laboratoire	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
4021	Revue	Guichard N, Bonnabry P, Rudaz S, Fleury S. Long-term stability of ganciclovir in polypropylene containers at room temperature. J Oncol Pharm Practice 2017 ;25,2: 303-308
4521	Revue	Polo C, D'Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020



# Dictionnaire

 Antiviral	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 Chlorure de sodium 0,9%	 Non précisée
 Jour	 Polyvinyl chlorure
 NaCl 0,9% ou glucose 5%	 A l'abri de la lumière
 Glucose 5%	 Polypropylène
 Seringue polypropylène	 Lumière
 Heure	 Elastomère en polyisoprène
 Facteur influençant la stabilité	 Solvant
 Nutrition parentérale (mélange ternaire)	 Provoque
 Dégradation	 Nutrition parentérale (mélange binaire)
 Compatibilités	 Molécule
 Compatible	 Précipitation immédiate
 Incompatible	 Précipitation en 30 minutes
 Instabilité chimique	 Incompatibilité non précisée
 Changement de couleur à 4 heures	 Aucun
 Précipitation en 1 heure	 Précipitation en 4 heures
 Voie d'administration	 Perfusion intraveineuse
 Intravitréenne	 Bibliographie
 Dictionnaire	